Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
14.77
+0.47 (3.29%)
At close: Nov 4, 2026, 4:00 PM EST
14.78
+0.01 (0.07%)
After-hours: Nov 4, 2026, 7:59 PM EST
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 86.71B INR in the quarter ending September 30, 2026, a decrease of -1.53%. This brings the company's total for the last twelve months to 329.84B, down -3.72% year-over-year. In the fiscal year ending March 31, 2026, Dr. Reddy's Laboratories had annual revenue of 335.93B with 3.19% growth.
Revenue (ttm)
329.84B INR
Revenue Growth
-3.72%
P/S Ratio
3.52
Revenue / Employee
11,982,526 INR
Employees
27,527
Market Cap
12.09B USD
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full Dr. Reddy's Laboratories breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 335.93B | 10.40B | 3.19% |
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
| Mar 31, 2019 | 153.85B | 11.82B | 8.32% |
| Mar 31, 2018 | 142.03B | 1.22B | 0.87% |
| Mar 31, 2017 | 140.81B | -13.90B | -8.98% |
| Mar 31, 2016 | 154.71B | 6.52B | 4.40% |
| Mar 31, 2015 | 148.19B | 16.02B | 12.12% |
| Mar 31, 2014 | 132.17B | 15.90B | 13.68% |
| Mar 31, 2013 | 116.27B | 19.53B | 20.19% |
| Mar 31, 2012 | 96.74B | 22.04B | 29.51% |
| Mar 31, 2011 | 74.69B | 4.42B | 6.28% |
| Mar 31, 2010 | 70.28B | 836.00M | 1.20% |
| Mar 31, 2009 | 69.44B | 19.44B | 38.87% |
| Mar 31, 2008 | 50.01B | -79.27B | -61.32% |
| Mar 31, 2007 | 129.28B | 80.94B | 167.42% |
| Mar 31, 2006 | 48.34B | 9.70B | 25.10% |
| Mar 31, 2005 | 38.65B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Viatris | 14.74B |
| Zoetis | 9.53B |
| Elanco Animal Health | 5.02B |
| Neurocrine Biosciences | 3.70B |
| Amneal Pharmaceuticals | 3.20B |
| United Therapeutics | 3.19B |
| Hims & Hers Health | 2.58B |
| Alkermes | 1.75B |
RDY News
- 1 day ago - Reddy's Gets Tentative FDA Nod For Twice-Yearly HIV Prevention Shot At $40 A Year - Nasdaq
- 2 days ago - Dr Reddy's gets tentative US FDA nod for generic HIV prevention - Reuters
- 2 days ago - Dr Reddy’s gets USFDA nod for first generic twice-yearly injectable HIV prevention drug Lenacapavir - The Times of India
- 6 days ago - Dr. Reddy's Laboratories Limited Announces USFDA Classifies FTO-SEZ Process Unit-02 Inspection as Voluntary Action Indicated - Nasdaq
- 10 days ago - Dr. Reddy’s upgraded to Hold from Underperform at Jefferies - TheFly
- 10 days ago - Dr. Reddy’s upgraded to Neutral from Underweight at JPMorgan - TheFly
- 10 days ago - Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors - The Motley Fool
- 12 days ago - Dr. Reddy's Laboratories Limited Reports Q2 FY 2027 Financial Results - Nasdaq